Skip to content

Clinical Press Releases: Santen Pharmaceutical establishes a safety database with ArisGlobal's LifeSphere® MultiVigilance multi-tenant drug safety suite to improve and streamline pharmacovigilance at a global scale

MIAMI, FL. and TOKYO, JAPAN, SEPTEMBER 18, 2019 – Santen Pharmaceutical Co., Ltd., the leader in ophthalmic drug development, has selected ArisGlobal to create a single global safety database and improve the efficiency and quality of their global safety vigilance processes. Santen Pharmaceutical’s safety suite will include ArisGlobal’s LifeSphere® MultiVigilance (LSMV), LifeSphere® Reporting and Analytics and LifeSphere® Intake and Triage solutions to automate key safety vigilance activities, reduce costs, and increase compliance.

“LSMV’s advanced artificial intelligence (AI) and machine learning automates repetitive manual tasks, improving efficiency and compliance levels. Switching to LSMV makes our team dramatically more efficient”, added Dr. Shimada, head of global safety vigilance at Santen Pharmaceutical.

Santen joins more than 250 life science companies, including 9 regulatory authorities, who use ArisGlobal’s safety, medical affairs, clinical and regulatory solutions, benefiting from rapid implementation on a multi-tenant cloud with upgrades delivered seamlessly.

“We are very pleased that Santen Pharmaceutical will adopt ArisGlobal’s multi-tenant LifeSphere® Safety suite,” said Sankesh Abbhi, ArisGlobal’s President and CEO. “We offer the world’s largest and most innovative multi-tenant safety cloud and Santen is an example of how customers in Japan and globally can meet a wide range of requirements for patient safety by leveraging our leading technology.” 

In addition, Santen will adopt ArisGlobal’s rapid migration methodology, which has been successfully embraced by many of the world’s leading life sciences companies when transitioning from their legacy safety systems. “Our tested and repeatable methodology has proven highly effective as we become the preferred safety cloud solution for major pharma,” added Abbhi. “We’re able to drastically reduce the traditional challenges of data migration, change management and user training, reducing transition risk and bringing necessary peace of mind.”


About Santen Pharmaceutical

As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan and its products now reach patients in over 60 countries. With scientific knowledge and organizational capabilities nurtured over a nearly 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society. For more information, please visit Santen’s website (

Download ArisGlobal’s 2024 Industry Report   Learn More

Join us at Breakthrough 2024 to explore life sciences transformation through Intelligent Automation

Registration is closed!